Sun, Mar 1, 2015, 10:48 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

  • uirapuru0 uirapuru0 Dec 20, 2012 12:52 PM Flag

    Affymax poised to Snap Back

    Seeking Alpha
    By Dee Kotak

    A number of factors have come together to create weakness in Affymax, Inc. (AFFY) providing a buying opportunity. On Wednesday, AFFY closed at $19.51, down 30% from its October high. The high volume down day was most likely precipitated by Piper Jaffray stating that the U.S. Government Accountability Office published a report on December 7 that recommended that Congress require the Department of Health and Human Services to rebase the End Stage Renal Disease bundle, as Erythropoiesis Stimulating Agent ((ESA)) utilization saw a 31% decline from 2007 to 2011, which is the year in which the bundle is based. Piper thinks that a reduction in the bundle has grown more probable, and that dialysis providers will probably require more discounts from drug manufacturers. The statement, combined with a decrease in script data last month and a small amount of insider selling, led to the sell-off. This was an overreaction, as the fundamentals supporting adoption and use of Omontys, AFFY's lead product, are strong and not significantly changed.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.1501+0.0001(+0.07%)Feb 27 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Celgene Corporation
NASDAQFri, Feb 27, 2015 4:00 PM EST